Nicotine therapeutic benefits: Difference between revisions
Moving suggestions to their categories |
adding category - Legionella Pneumophila |
||
| Line 583: | Line 583: | ||
<br> | <br> | ||
='''Infection, Inflammation, "Cytokine Storm"'''= | ='''Infection, Inflammation, "Cytokine Storm"'''= | ||
===2013 [https://journals.asm.org/doi/10.1128/cvi.00636-12 Targeting the “Cytokine Storm” for Therapeutic Benefit]=== | |||
*Nicotine is a nonselective agonist of the α7Ach receptor and is able to suppress the production of proinflammatory cytokines by mimicking the binding of acetylcholine. It has been demonstrated that nicotine can selectively reduce the inflammatory response in a number of infection scenarios, including Legionella pneumophila (54) and Chlamydia pneumoniae (55) infection... | |||
*Citation: D'Elia, R. V., Harrison, K., Oyston, P. C., Lukaszewski, R. A., & Clark, G. C. (2013). Targeting the "cytokine storm" for therapeutic benefit. Clinical and vaccine immunology : CVI, 20(3), 319–327. https://doi.org/10.1128/CVI.00636-12 | |||
<br> | |||
='''Legionella Pneumophila (Legionnaires' disease)'''= | |||
===2013 [https://journals.asm.org/doi/10.1128/cvi.00636-12 Targeting the “Cytokine Storm” for Therapeutic Benefit]=== | ===2013 [https://journals.asm.org/doi/10.1128/cvi.00636-12 Targeting the “Cytokine Storm” for Therapeutic Benefit]=== | ||